● pepmg Research Desk · Peer-reviewed evidence review
What the research says about methylene blue
A neutral summary of the peer-reviewed literature on methylene blue, an old synthetic dye with established emergency uses and largely preclinical claims around cognition and aging. Research use only.
Limited evidence — Early or small human data, or strong preclinical work. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Methylene blue is one of the oldest synthetic drugs, with established clinical uses as an antidote for methemoglobinemia, for vasoplegic (vasodilatory) shock, and as an antimalarial and diagnostic dye [1][2].
- The uses research-chemical vendors emphasize (cognitive enhancement, anti-aging, neuroprotection) rest largely on preclinical and early-phase work on its mitochondrial and antioxidant effects, not on confirmatory human trials [3][6].
- A key safety point: methylene blue is a potent monoamine oxidase-A inhibitor, and a systematic review documented serotonin syndrome when it was combined with serotonergic medications [7][8].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What methylene blue is
Methylene blue (methylthioninium chloride) is described in the literature as the first fully synthetic medicine, with a long history of clinical use [3]. Reviews list its established roles as an antidote for toxin-induced and hereditary methemoglobinemia, for ifosfamide-induced encephalopathy and cyanide poisoning, as an antimalarial agent, and as a surgical staining dye [2][8]. Pharmacologically it can act as an alternative electron carrier in mitochondria and as an inhibitor of nitric oxide synthase and guanylate cyclase [3][6].
Material sold by third-party research-chemical vendors is not the pharmaceutical-grade product used in those clinical settings and is offered for laboratory and research use only.
What the human research has measured
Limited evidenceThe best-supported human uses are acute and hospital-based. Reviews describe methylene blue as an adjunct in vasoplegic syndrome and other shock states, where it is proposed to raise blood pressure by interfering with the nitric-oxide/cyclic-GMP pathway, though the authors note a paucity of prospective data guiding its use [1][2]. Its role as a methemoglobinemia antidote is long established [8].
The claims most relevant to the research-chemical market are less settled. A review of methylene blue as a potential anti-aging drug summarizes preclinical work on neurodegeneration, memory, and skin aging based on its mitochondrial and antioxidant effects, framing these as areas of new interest rather than proven applications [3]. Reviews of its potential in traumatic brain injury, ischemia, and Alzheimer's disease likewise describe experimental (cell and animal) neuroprotection [6], and a review of experimental stroke models notes neuroprotective signals in animals [5]. On mood, a review notes that methylene blue has shown antidepressant and anxiolytic activity in preclinical models and early clinical trials for schizophrenia and bipolar disorder, attributing this partly to its monoamine oxidase-A inhibition [8].
What the trials report on safety and adverse events
Limited evidenceThe most clearly documented risk is a drug interaction. A systematic review identified case reports and retrospective reviews in which 26 patients developed an acute confusional state after methylene blue infusion; 24 of them were taking a serotonin-reuptake inhibitor, and serotonin syndrome was a possible diagnosis in nearly all, reflecting methylene blue's action as a monoamine oxidase-A inhibitor [7].
A narrative toxicology review reported that the toxic effects of methylene blue are dose-dependent and can include hemolysis, methemoglobinemia (at higher exposures), nausea and vomiting, chest pain, shortness of breath, and hypertension, and it emphasized that the basic toxicological profile of the substance remains incompletely characterized [10]. Reviews of its use in shock states also note side effects that constrain dosing [1].
These are reports and observations from clinical and case literature, not a safety guarantee and not a prediction for any individual. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence is characterized as limited for the uses the research-chemical market emphasizes. Methylene blue has genuine, established roles in emergency medicine (methemoglobinemia, vasoplegia), but its cognitive, anti-aging, and neuroprotective claims rest mainly on preclinical and early-phase studies rather than confirmatory randomized human trials [1][3][6]. "Limited" describes the maturity of the research behind those marketed uses, not a verdict that methylene blue does or does not work.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 8
- Methylene Blue for Vasoplegic Syndrome.
- A review of methylene blue treatment for cardiovascular collapse.
- The Potentials of Methylene Blue as an Anti-Aging Drug.
- Methylene blue treatment in experimental ischemic stroke: a mini review.
- Methylene blue and its potential in the treatment of traumatic brain injury, brain ischemia, and Alzheimer's disease.
- The role of methylene blue in serotonin syndrome: a systematic review.
- Methylene blue and its analogues as antidepressant compounds.
- Methylene blue: a controversial diagnostic acid and medication?
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.